Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Sponsor
Peking University Cancer Hospital & Institute
Study ID
NCT06360042
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.

Key Dates

Start date
Jan 1, 2024
Status verified
Nov 2023
Primary completion
Mar 31, 2027
Completion
Mar 31, 2028

Study Design

Enrollment
111 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Adebrelimab（1200mg iv q3w） plus Apatinib(250mg po qd)
  • Experimental: 2
    Adebrelimab（1200mg iv q3w）plus Bevacizumab(15mg/kg iv q3w)
  • Experimental: 3
    Camrelizumab (200mg iv q2w) plus Apatinib(250mg po qd)

Primary Outcome Measure

12-month overall survival rate [ Time Frame: Up to approximately 3 years ]

Central Contacts

Related Studies